The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations more particularly for the treatment of pain.

The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics, more particularly for the treatment of severe to moderate pain with an inflammation component.

The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics more particularly for the treatment of severe to moderate pain with an inflammation component.

The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics more particularly for the treatment of severe to moderate pain with an inflammation component.

The invention provides methods of reducing the side effects of tramadol. Accordingly in one embodiment the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking the tramadol material. The invention also provides pharmaceutical compositions. In one embodiment the composition comprises a tramadol material and a phos...

The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking the tramadol material. The invention also provides pharmaceutical compositions. In one embodiment, the composition comprises a tramadol material and a p...

An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.